In an interview about the efficacy of COVID-19 vaccines, Richard Marlink, the director of Rutgers Global Health Institute, responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States. The following is an excerpt from the story published by ROI-NJ: When the news that Johnson & Johnson had completed Phase 3 of its clinical trial and that its one-shot vaccine would soon be available finally was released Friday morning, there was unbridled excitement. It would be a game-changer, many said. To read the full story.
Recent Posts
- How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
- Amid Trump’s ire, can Harvard afford to lose federal research funds?
- Most residents don’t know N.J. offers medical aid in dying, survey finds.
- Rutgers Researchers Revive Decades-Old Pregnancy Cohort with Modern Scientific Potential.
- Spring allergy season returns to NJ. How bad will it be?
Categories
- Community (2,220)
- Covid (985)
- CTO Events (6)
- News (2,831)
- Pilots (21)